NASDAQ: KZIAKazia Therapeutics Ltd Stock
$12.00-0.31 (-2.52%)
Updated Aug 5, 2026
KZIA Price
$12.00
Fair Value Price
$2.51
Market Cap
$680.16M
52 Week Low
$4.86
52 Week High
$17.40
P/E
-7.96x
P/B
20.64x
P/S
43.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.35M
Earnings
-$15.30M
Gross Margin
100%
Operating Margin
-1,285.72%
Profit Margin
-1,200.9%
Debt to Equity
0.53
Operating Cash Flow
-$10M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KZIA Overview
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KZIA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KZIA
Ranked#88 of 465
Ranked#88 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.75 | A | |
| $110.69 | A | |
| $8.11 | A |
Be the first to know about important KZIA news, forecast changes, insider trades & much more!
KZIA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KZIA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KZIA ($12.00) is overvalued by 378.34% relative to our estimate of its Fair Value price of $2.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KZIA ($12.00) is not significantly undervalued (378.34%) relative to our estimate of its Fair Value price of $2.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KZIA due diligence checks available for Premium users.
Valuation
KZIA fair value
Fair Value of KZIA stock based on Discounted Cash Flow (DCF)
Price
$12.00
Fair Value
$2.51
Overvalued by
378.34%
KZIA ($12.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KZIA ($12.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KZIA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.96x
Industry
14.89x
Market
14.23x
KZIA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.64x
Industry
5.31x
KZIA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KZIA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
KZIA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KZIA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$47.7M
Liabilities
$16.5M
Debt to equity
0.53
KZIA's short-term assets ($49.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZIA's short-term assets ($49.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZIA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KZIA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
KZIA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KZIA vs Biotech Stocks
Kazia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.